13 Amendments of Aldo PATRICIELLO related to 2020/2076(INI)
Amendment 35 #
Motion for a resolution
Recital A
Recital A
A. whereas the Union requires a new industrial strategy that makerenders its industries more globally competitive, resilient and environmentally sustainable; whereas such a strategy should cover the transition of European industries to digitaliszation and climate-neutrality, prioritiszing the ‘energy efficiency first’ principles, energy savings and renewable energy technologies, and support a robust European value chain in innovative renewable and clean technologies;
Amendment 187 #
Draft opinion
Paragraph 6 a (new)
Paragraph 6 a (new)
6a. Urges the Commission, following the COVID-19 crisis and the clear need for a pan-European coordination and dialogue to guarantee access for patients to their treatments, to create an ad-hoc platform with policy-makers, authorities, the pharmaceutical industry and relevant stakeholders of the healthcare supply chain to define and agree on a common roadmap;
Amendment 195 #
Draft opinion
Paragraph 6 b (new)
Paragraph 6 b (new)
6b. Recalls the importance of a sustainable and competitive pharmaceutical industrial sector to ensure sustainable access to medicines for patients, as demonstrated during the COVID-19 health crisis; in order to secure existing production investments in Europe, ensuring long-term sustainability, competitiveness and security of supply, calls on the Commission to support Member States by specifically developing ad hoc EU Guidelines on sustainable procurement of medicines, under the current EU public procurement rules, looking at criteria beyond the lowest price only, notably by implementing the so-called MEAT criteria;
Amendment 203 #
Draft opinion
Paragraph 6 c (new)
Paragraph 6 c (new)
6c. Urges the Commission and Member States to put the right economic framework in place to secure and modernize existing manufacturing capabilities of medicines, technology and Active Pharmaceutical Ingredients (APIs) in Europe, for example by rewarding investments in medicines quality and security of supply;
Amendment 264 #
Motion for a resolution
Paragraph 8
Paragraph 8
8. Is of the opinion that the industrial recovery plan should help to createing new ambitious and innovative European industrial projects, which go hand in hand with the current revision of the guidelines for ‘ImportMajor Europeant Projects of Common European Interest’ (IPCEI),MEPCIs) in order to encourage the emergence of European leaders in strategic industrial sectors that are capable of competing on a global scale and that will contribute to achieving a climate- neutral, renewable-based energy system;
Amendment 423 #
Motion for a resolution
Paragraph 14
Paragraph 14
14. Considers that there is significant potential in domestic and global markets for low-emission and renewable technologies and, sustainable products, processes and services throughoutacross the whole value chain from raw materials to, energy- intensive industries, manufacturing and the industrial services sector; moreover considers, moreover, that the Climate Law isto be a first step towards enshrining climate targets into Union legislation; believes that, in addition, a more holistic and systematic targets’ framework is also required in order to ensure policy coherence across all Union policies and an homogenous governance approach in all policy areas, pavingwhich would pave the way towards a clear and stable strategy for the European industries;
Amendment 447 #
Motion for a resolution
Paragraph 15
Paragraph 15
15. Maintains that a truly effective European industrial policy needs a dashboard of climate targets as a roadmap to shape the industry of the future; considers that all sectors should contribute towards achieving the Union’s climate objectives and, in this regard, underlinerecalls the importance of gas as a means of energy transition and hydrogen as a potential breakthrough technology; calls also for greater attention to be paid to network ssecuring climate-neutral energy at globally competitive prices for industries, and to this end the need to accelerate the development and integration of renewable capacities in the energy mix and to facilitate the deployment of hydrogen production based on renewable elecutricity and energy supplyits use in hard-to-abate sectors; calls on the Council to increase spending from the EU budget on climate change efforts to at least 30% of the budget; calls on the Commission to ensure that industries with high carbon leakage do not benefit from EU subsidies, and for better use to be made of the EIB, as the Union’s ‘Climate Bank’, to enhance sustainable financing to the public and private sectors and to assist companies in the decarbonisation process, and to use the Border Carbon Adjustments mechanism as a way to protect EU manufacturers and jobs from unfair international competition;
Amendment 530 #
Motion for a resolution
Paragraph 17
Paragraph 17
17. Calls on the Commission to tailor its industrial strategy to the scaling- up and the commercialisation of breakthrough technologies in the Union, by providing risk financing tools for early-stage technology and developing early value chains to support first commercial-scale, climate- neutral and renewable technologies and products;
Amendment 588 #
Motion for a resolution
Paragraph 19 a (new)
Paragraph 19 a (new)
19a. Calls on the Commission to ensure its next pharmaceutical strategy will foster research, innovation and manufacturing in the EU, by way of an intellectual property system that promotes investments in medical research and a stable, effective and globally competitive regulatory framework;
Amendment 602 #
Motion for a resolution
Paragraph 20
Paragraph 20
20. Considers that industrial transformation requires the integration of new knowledge and innovation to be integrated into existing markets and their use in the creation ofo create new ones; regrets, in this respect, that the Union invests less in R&D as a percentage of GDP than its global competitors and that it suffers from a serious lack of innovative capacity in small and medium-sized enterprises due to a shortfall inthe lack of the necessary risk capital; calls on the Commission to increase the budget for those programmes that underpin the transformation of the Union’s industry, including Horizon Europe, create appropriate funding instruments for the market development of breakthrough technologies supported by the set-up of the European Innovation Council and to foster synergies between regional, national, European and private financial sources by, taking advantage of synergies amongst all Union programmes;
Amendment 645 #
Motion for a resolution
Paragraph 21
Paragraph 21
21. Is of the opinion that ecosystems will be key components of the next industrial revolution, providing affordable and cleaner energy, transformative manufacturing and service-provision methods; believes, moreover,moreover believes that, supporting collaboration among industry, academia, SMEs, start-ups, trade unions, civil society, end-user organisations and all other stakeholders will be key toin solving market failures and supporting efforts to crossthe crossing of the ‘valley of death’, includingalso in areas not yet covered by industrial interests;
Amendment 665 #
Motion for a resolution
Paragraph 22 a (new)
Paragraph 22 a (new)
22a. Recalls the importance of a sustainable and competitive pharmaceutical industrial sector to ensure sustainable access to medicines for patients, as demonstrated during the covid19 health crisis. In order secure existing production investments in Europe, ensuring long-term sustainability, competition and security of supply, calls on the Commission to support Member States by specifically developing ad hoc EU Guidelines on sustainable procurement of medicines, under the current public procurement directive, looking at criteria beyond the lowest price only, notably by implementing the so-called MEAT criteria;
Amendment 670 #
Motion for a resolution
Paragraph 22 b (new)
Paragraph 22 b (new)
22b. Following the covid19 crisis and the clear need for a pan-European coordination and dialogue to guarantee access for patients to their treatments, urges the Commission to create an ad-hoc platform with policy-makers, authorities, the pharmaceutical industry and relevant stakeholders of the healthcare supply chain to define and agree on a common roadmap and concrete actions and policies for example to ensure the sustainability and competitiveness of the pharmaceutical sector in Europe;